Grupo Supervielle Reports 2025 Financial Highlights
- Improved Financial Performance: Grupo Supervielle reported an attributable net loss of AR$19.5 billion in Q4 2025, a significant improvement from AR$54.2 billion in Q3, indicating a gradual normalization of financial conditions, although the full year still recorded a net loss of AR$48.6 billion due to monetary tightening pressures.
- Strong Loan Growth: As of December 31, 2025, total loans reached AR$3,982.9 billion, reflecting a 172.1% increase since March 2024, with a quarterly growth of 8.4% that outpaced the industry’s 2.0% expansion, showcasing the company's robust performance in commercial lending.
- Robust Capital Adequacy: The Common Equity Tier 1 (CET1) ratio stood at 15.4% as of December 31, 2025, increasing by 220 basis points quarter-over-quarter, indicating the company's strength and flexibility in capital management, despite a slight year-over-year decline.
- Accelerated Digital Transformation: Over 70% of transactions were completed through the mobile app, highlighting the shift towards digital services, with the SuperApp enhancing integration capabilities, further boosting client engagement and funding base, particularly with the addition of 114,000 payroll customers.
Trade with 70% Backtested Accuracy
Analyst Views on SUPV
About SUPV
About the author

- Significant Loan Growth: Grupo Supervielle reported an 8% sequential and 37% year-over-year increase in total loans in Q4 2025, with corporate loans now representing 63% of the portfolio, indicating a strategic focus on risk-adjusted returns amidst market volatility.
- Asset Quality Pressure: Despite strong management performance, the NPL ratio rose to 5% and cost of risk reached the upper guidance range, reflecting the impact of systemic credit stress, necessitating close monitoring of asset quality stability moving forward.
- Accelerated Digital Transformation: With over 70% of transactions being digital, the Supervielle app is positioned as a central financial hub, aiming to enhance operational efficiency and customer engagement through ecosystem integration and targeted cross-selling of high-value clients.
- Optimistic Outlook: The company expects loan growth of 25% to 30% and deposit growth of 20% to 25% in 2026, with NPL ratios projected to fluctuate between 5% and 6%, demonstrating confidence in market recovery and strategic positioning for future demand.
- Net Loss Overview: Grupo Supervielle reported an attributable net loss of AR$19.5 billion in Q4 2025, an improvement from a net loss of AR$54.2 billion in Q3 2025, indicating initial success in financial management despite ongoing challenges.
- Financial Margin Growth: The net financial margin for Q4 reached AR$245.7 billion, reflecting an 82.2% increase quarter-over-quarter and a 1.3% increase year-over-year, showcasing significant progress in profitability enhancement amidst a tough market environment.
- Total Assets Fluctuation: As of December 31, 2025, total assets stood at AR$7,791.5 billion, down 3.1% quarter-over-quarter but up 30.7% year-over-year, highlighting the dual challenges and opportunities in asset management and market expansion for the company.
- Market Outlook: Despite the reported losses, Grupo Supervielle's financial metrics suggest ongoing efforts to improve profitability and asset growth, which may attract investor interest, particularly in the context of Argentina's economic recovery.
- Improved Financial Performance: Grupo Supervielle reported an attributable net loss of AR$19.5 billion in Q4 2025, a significant improvement from AR$54.2 billion in Q3, indicating a gradual normalization of financial conditions, although the full year still recorded a net loss of AR$48.6 billion due to monetary tightening pressures.
- Strong Loan Growth: As of December 31, 2025, total loans reached AR$3,982.9 billion, reflecting a 172.1% increase since March 2024, with a quarterly growth of 8.4% that outpaced the industry’s 2.0% expansion, showcasing the company's robust performance in commercial lending.
- Robust Capital Adequacy: The Common Equity Tier 1 (CET1) ratio stood at 15.4% as of December 31, 2025, increasing by 220 basis points quarter-over-quarter, indicating the company's strength and flexibility in capital management, despite a slight year-over-year decline.
- Accelerated Digital Transformation: Over 70% of transactions were completed through the mobile app, highlighting the shift towards digital services, with the SuperApp enhancing integration capabilities, further boosting client engagement and funding base, particularly with the addition of 114,000 payroll customers.
- Narrowed Net Loss: In Q4 2025, Grupo Supervielle reported an attributable net loss of AR$19.5 billion, a significant improvement from AR$54.2 billion in Q3, reflecting a gradual normalization of financial conditions and revenue recovery.
- Rebounding Net Interest Margin: The net interest margin rebounded to 19% in Q4, up from 10.8% in Q3, primarily driven by lower funding costs and recovering investment portfolio yields, indicating positive progress in enhancing profitability.
- Strong Loan Growth: As of December 31, 2025, total loans reached AR$3,982.9 billion, representing a 36.9% year-on-year increase, outpacing industry averages, which demonstrates the effectiveness of the company's credit expansion strategy.
- Robust Capital Ratio: The Common Equity Tier 1 (CET1) ratio stood at 15.4% as of December 31, 2025, increasing by 220 basis points quarter-over-quarter, reflecting the company's ongoing efforts in capital management and risk control.

Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing new ratings and price targets for investors to consider.
Option Care Health Inc: Raj Kumar from Stephens & Co. rated Option Care Health Inc (OPCH) as Overweight with a price target of $40, while the stock closed at $33.09.
Grupo Supervielle SA: Itau BBA's Pedro Leduc rated Grupo Supervielle SA (SUPV) as Outperform with a price target of $15, with shares closing at $10.70.
Oscar Health Inc and BridgeBio Pharma Inc: Dean Sublett from Stephens & Co. rated Oscar Health Inc (OSCR) as Equal-Weight with a target of $17, and William Pickering from Bernstein rated BridgeBio Pharma Inc (BBIO) as Outperform with a target of $94, with respective closing prices of $15.59 and $72.70.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.




